## Abstract The most widely used scale currently available for the clinical evaluation of motor dysfunction in Parkinson's disease (PD)—the Unified Parkinson's Disease Rating Scale‐III (UPDRS‐III) —is time‐consuming, subjective, and has suboptimal sensitivity. A brief timed motor test (TMT) battery
Prognosis of Parkinson's disease: Time to stage III, IV, V, and to motor fluctuations
✍ Scribed by Kenichi Sato; Taku Hatano; Kazuo Yamashiro; Maki Kagohashi; Kenya Nishioka; Nana Izawa; Hideki Mochizuki; Nobutaka Hattori; Hideo Mori; Yoshikuni Mizuno
- Book ID
- 102502937
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- English
- Weight
- 259 KB
- Volume
- 21
- Category
- Article
- ISSN
- 0885-3185
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
We report a long‐term outcome on a large cohort of Japanese patients with Parkinson's disease (PD). A total of 1,768 (793 men, 975 women) consecutive patients visited our clinic from 1 January 1989 to 31 December 2002. Among them, 1,183 patients (531 men, 652 women) came to our clinic within 5 years from the onset of disease and at the Hoehn & Yahr Stage III or less at the first visit. Long‐term outcome was evaluated in this subcohort of the patients. We examined the duration to reach Stage III, IV, and V, and the duration to develop wearing off and dyskinesia. Time to reach Stage III was slightly but significantly shorter in women, in that 23.8% of men and 35.3% of women reached Stage III by the end of the 5th year; 49.7% of men and 63.3% of women reached Stage III by the end of the 10th year, and 88.9% of men and 79.9% of women by the end of the 15th year (P < 0.001). Also, durations to develop wearing off and dyskinesia were shorter in women compared to men. These data suggest that the disease progression may be slightly faster for women. Young‐onset patients showed significantly longer duration to reach Stage III, IV, and V but shorter duration to develop wearing off and dyskinesia. Not many studies are available in the literature on the long‐term outcome of PD, and our data would be useful as a reference. © 2006 Movement Disorder Society
📜 SIMILAR VOLUMES
Thirty-four patients with Parkinson's disease were followed for a mean period of 8 years from the time of initiation of levodopa medication. Levodopa response was charted from the starting point of pharmacological treatment to give a longitudinal point of view of the changes that evolve as the disea
## Abstract In this 12‐week, randomized, open‐label, blinded‐rater, parallel‐group trial, the efficacy, safety, and tolerability of tolcapone and pergolide were compared in parkinsonian patients with a fluctuating response to levodopa. Patients received tolcapone 100 mg three times daily (t.i.d.),